Видео ютуба по тегу Anti–Pd-1

Cancer immunotherapy | The PD-L1 pathway
Cancer immunotherapy | The PD-L1 pathway
PD-L1/PD-1 Pathway: A Security Checkpoint
PD-L1/PD-1 Pathway: A Security Checkpoint
Toxicities Associated with Anti–PD-1 Immunotherapy
Toxicities Associated with Anti–PD-1 Immunotherapy
Beyond anti-PD-1 and anti-CTLA-4 in melanoma
Beyond anti-PD-1 and anti-CTLA-4 in melanoma
Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers
Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers
Dr. Topalian on Biomarkers for Anti- PD-1 Therapies in Melanoma
Dr. Topalian on Biomarkers for Anti- PD-1 Therapies in Melanoma
Moffitt Medical Minute (Ep. 29) - Anti-PD-1 Therapy
Moffitt Medical Minute (Ep. 29) - Anti-PD-1 Therapy
AON 2024 | Antibody-Drug Conjugates in Lung Cancer — Edward B Garon, MD, MS
AON 2024 | Antibody-Drug Conjugates in Lung Cancer — Edward B Garon, MD, MS
Explaining Immunotherapy, PD-L1 and PD-1
Explaining Immunotherapy, PD-L1 and PD-1
Understanding and Overcoming Resistance to Anti-PD-1 Immunotherapy in Melanoma
Understanding and Overcoming Resistance to Anti-PD-1 Immunotherapy in Melanoma
Anti–PD-1 Therapy in Metastatic Melanoma
Anti–PD-1 Therapy in Metastatic Melanoma
Cancer Immunotherapy - PD-1 and PD-L1
Cancer Immunotherapy - PD-1 and PD-L1
Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways
Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways
PD-L2 expression and its relevance to anti-PD-1 therapy in cancer
PD-L2 expression and its relevance to anti-PD-1 therapy in cancer
Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhD
Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhD
MEDI5752: Novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors
MEDI5752: Novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors
Where to go next with pembrolizumab and other anti-PD-1 therapies in head and neck cancer
Where to go next with pembrolizumab and other anti-PD-1 therapies in head and neck cancer
Anti–PD-1 Adjuvant Therapy in Melanoma
Anti–PD-1 Adjuvant Therapy in Melanoma
Planned 2024 studies in anti-PD-1 resistance
Planned 2024 studies in anti-PD-1 resistance